Atazanavir/ritonavir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Atazanavir/ritonavir
Combination of
AtazanavirProtease inhibitor
RitonavirProtease inhibitor (pharmacokinetic booster)
Clinical data
SynonymsAnzavir-R, ritonavir/atazanavir[1]
Routes of
administration
By mouth[1]
ATC code

Atazanavir/ritonavir (ATV/r) is a combination medication used in the treatment of HIV/AIDS.[1] It combines atazanavir and ritonavir.[1] It may be used instead of lopinavir/ritonavir.[2] It is taken by mouth.[1]

Side effects are generally minimal.[2] They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache.[2] Greater care should be taken in people with underlying liver problems.[2] Use in pregnancy appears to be safe.[3] In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.[2]

The combination was approved for use in India in 2012 and is pending approval in the US as of 2017.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] The average cost per year is 281 USD in the developing world as of 2012.[2]

References[edit]

  1. ^ a b c d e f "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017.
  2. ^ a b c d e f "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
  3. ^ "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Retrieved 10 December 2017.
  4. ^ "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.